amyloid-beta
2 articles · search the full text for this term
-
Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes
Abstract: Background: Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and loss of independence. Despite decades of extensive research, disease-modifying treatments have been limited in success. Recent therapeutic advancements have led to the development of monoclonal antibodies targeting amyloid-beta (Aβ) plaques, particularly the pyroglutamate-modified variant, a key pathological hallmark of AD. Objectives: This review aims to explore the therapeutic potential of Donanemab (Kisunla), a novel …
Published in Research and Reviews: A Journal of Neuroscience · Vol. 15, Issue 3, 2025 · pp. 37–45 Read article
-
Study on Chemical Insights into Alzheimer's Disease: Amyloid Beta and Tau Protein Interactions
Abstract: Background: Alzheimers disease (AD) is the most prevalent form of dementia, affecting millions of individuals worldwide and posing significant challenges to healthcare systems. The disease is characterized by a gradual decline in cognitive functions, particularly memory, reasoning, and the ability to perform daily activities. Aim & objective: To study chemical insights in alzheimers disease, especially amyloid beta and tau protein interactions Results & discussion: The results of this review highlight …
Published in International Journal of Brain Sciences · Vol. 2, Issue 1, 2025 · pp. 37–46 Read article